Skip to content

AbCellera Biologics

US · ABCL #2215 by market cap Listed 2020
9.69 -0.78 -7.45%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:59

Quant vs Street three independent views, side by side

StockVane factor grade
A-
Momentum strategy signal
Hold
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 9 analysts

Buy
Avg price target 19.33 +99.5%
Price target rangecurrent 9.69
Low14.00
Avg19.33
High30.00
Buy 89% Hold 11% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-12 UBS -- Buy 18.00
2026-11-10 JonesTrading -- Buy 25.00
2026-11-10 Stifel -- Buy 14.00
2026-11-10 BMO Capital -- Buy 15.00
2026-11-10 J.P. Morgan -- Buy 17.00
2026-11-09 Cantor Fitzgerald -- Buy 20.00
2026-11-09 Goldman Sachs -- Hold 14.00
2026-10-30 Jefferies -- Buy 21.00
2026-10-12 UBS -- Buy 18.00
2026-09-29 J.P. Morgan -- Buy 17.00
2026-09-27 JonesTrading -- Buy 25.00
2026-09-24 Goldman Sachs -- Hold 13.00
2026-09-02 Truist Financial -- Buy 30.00
2026-08-17 BMO Capital -- Buy 15.00
2026-08-11 Truist Financial -- Buy 30.00
2026-08-10 JonesTrading -- Buy 25.00
2026-08-10 Truist Financial -- Buy --
2026-08-10 BMO Capital -- Buy 15.00
2026-08-07 Piper Sandler -- Buy 12.00
2026-08-06 Stifel -- Buy 9.00
2026-08-05 TD Cowen -- Buy --
2026-08-05 Cantor Fitzgerald -- Buy 12.00
2026-07-31 Piper Sandler -- Buy 12.00
2026-07-29 JonesTrading -- Buy 13.00
2026-07-16 Cantor Fitzgerald -- Buy 11.00

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-09 After close ±12.92% -0.32% (in line)
2026/Q2 2026-08-05 After close ±18.10% +10.30% (in line)
2026/Q1 2026-05-11 After close ±12.86% -5.71% (in line)
2025/Q4 2026-02-24 After close ±22.38% -0.93% (in line)
2025/Q3 2025-11-06 After close ±18.54% -13.69% (in line)
2025/Q2 2025-08-07 After close ±26.18% +0.24% (in line)
2025/Q1 2025-05-08 After close ±35.07% +1.00% (in line)
2024/Q4 2025-02-27 After close ±30.79% -11.47% (in line)
2024/Q3 2024-11-04 After close ±19.34% -5.88% (in line)
2024/Q2 2024-08-06 After close ±15.79% -7.72% (in line)
2024/Q1 2024-05-07 After close ±19.36% -4.95% (in line)
2023/Q4 2024-02-20 After close ±19.57% -9.42% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 19:59:30 · For reference only, not investment advice and not tailored to your situation.

AbCellera Biologics discussion 0 comments

Add a comment